OverviewChartNewsTraderScreen

UBS Knock-Out IDP/  DE000UM2U146  /

UBS Investment Bank
2024-11-14  9:56:30 PM Chg.-0.009 Bid- Ask- Underlying Strike price Expiration date Option type
0.154EUR -5.52% -
Bid Size: -		 -
Ask Size: -		 BIOGEN INC. DL -,000... 150.1384 - 2078-12-31 Call
TeleTrader 10-30 Biogen's Q3 revenue down 3% to $2.5 billion
TeleTrader 08-01 Biogen books $2.5 billion in Q2 revenue
GlobeNewswire 07-30 New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecane...
GlobeNewswire 07-30 Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Path...
GlobeNewswire 07-26 Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
GlobeNewswire 07-02 Biogen Completes Acquisition of Human Immunology Biosciences
GlobeNewswire 06-28 “LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China
GlobeNewswire 06-24 TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union
GlobeNewswire 06-10 FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application f...
GlobeNewswire 06-03 Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of ...
GlobeNewswire 05-30 Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a R...
GlobeNewswire 05-22 Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Im...
GlobeNewswire 05-21 Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors
GlobeNewswire 05-16 Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lat...
GlobeNewswire 05-15 Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Su...
GlobeNewswire 05-02 Biogen Reports Progress on Corporate Responsibility Priorities
GlobeNewswire 04-25 Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEM...
TeleTrader 04-24 Biogen posts Q1 revenue of $2.3 billion
GlobeNewswire 04-23 Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immu...
GlobeNewswire 04-02 ADARx Pharmaceuticals Appoints Dr. Chris Storgard as Chief Medical Officer
GlobeNewswire 03-06 New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) i...
GlobeNewswire 03-04 Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (...
GlobeNewswire 02-23 Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positiv...
TeleTrader 02-13 Biogen's Q4 revenue falls 6% to $2.4 billion
GlobeNewswire 02-12 Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Tr...